ZURICH (Reuters) - Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.
Esbriet has been shown to slow the progression of IPF, and the new tablet formulation reduces the number of pills patients need to take, the Swiss drugmaker said in a statement on Tuesday.
(Reporting by Silke Koltrowitz; Editing by Michael Shields)
